bronchospasm
Respiratory · 2019–2020
2decisions
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| terbutaline Management of bronchospasm in patients unable to achieve coordinated use of a metered dose inhaler containing a short-acting beta-2 agonist, or in patients who… | Jul 2020 | Recommended | input received Lung Foundation Australia |
| terbutaline Treatment of bronchospasm in patients unable to use pressurised metered dose inhalers (pMDI) containing short-acting beta-2 agonists, or who have developed… | Jul 2019 | Recommended with restriction | no section in document |
Who spoke
Lung Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.